Inside Precision Medicine September 4, 2024
In a new $500M+ deal, Bayer and NextRNA Therapeutics will jointly develop two first-in-class small molecule programs targeting long non-coding RNA (lncRNA) in cancers. lncRNAs represent a vast class of therapeutic targets that recruit RNA-binding proteins (RBPs) to drive pathological processes across diseases. Disrupting lncRNA-RBP interactions with small molecules represents an innovative approach to develop a new class of therapeutic agents.
Approximately 75% of the genome is transcribed into RNAs that do not encode proteins, called non-coding RNAs (ncRNAs). A relatively new target for drug development, lncRNAs are RNA transcripts that are longer than 200 nucleotides. By definition, these RNAs must not have open reading frames that encode proteins.
“lncRNAs are a vast class of therapeutic targets that recruit...
Today's Sponsors
Today's Sponsor